Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
WHERE'S THE 10Q?
Can't wait for the 2010 10k filing. Looking for several key things:
- what is the real loss of revenue picture; year over year. Suspect it will be the same outcome as historical performance under Mr. Gogia.
- how Mr. Gogia explains the significant disparity between the stories for three pre-merger filings and the recent Q3 10Q filing regarding the true story of the default payments to Arnold Worldwide. Suddenly the default amount doubled. Mistake? False reporting? Will we see an SEC review?
We hold some great technology - do we have the appropriate leadership for our success?
selling shares , not good for the value of the stock it seems
The company has 45 days ,should be completed by March 15 2011.Let's see if their on time.
I think the sellers here will be kicking themselves, I think it's gonna blow up one day soon
Somethings gotta shake out with this IR Firm, they must have info to get out at some point here
Looks like they are selling a couple of shares here, what do you think?
http://yahoo.brand.edgar-online.com/displayfilinginfo.aspx?FilingID=7737566-966-16013&type=sect&TabIndex=2&companyid=696002&ppu=%252fDefault.aspx%253fcompanyid%253d696002%2526amp%253bformtypeID%253d1113
Shouldn't we have a 10Q today or soon?
NFRX nice forecast
Here's a nice forecast .... Link http://www.cpreports.com/?p=861
You Are Here: Home » CP Reports Blog » RAY DIRKS Research: NFRX.pk Feb 8, 2011 by Ray Dirks
RAY DIRKS Research: NFRX.pk Feb 8, 2011 by Ray Dirks
Posted on admin on February 9, 2011 // Leave Your Comment InferX Corporation (NFRX.pk) – $0.60
February 7, 2011
RAY DIRKS Research recommends InferX Corporation (NFRX.pk) at its current price of 60 cents per share for substantial capital appreciation over the next 6 months, 1 year, 3 years, and 5 years. Headquartered in Northern Virginia near the Dulles International airport, InferX’s top management team and its 25 full-time employees plus 30 consultants are capable of leading the accelerating worldwide trend of Predictive Analysis (PA) by utilizing its 6 key patents (2 granted and 4 pending) in such significant areas as healthcare, insurance, government, finance, retail, and sales and marketing of industrial products.
Specifically, RAY DIRKS Research believes that the common stock of InferX will appreciate by 100% within 3 months to $1.20, triple within 1 year to $1.80, appreciate by 10 times within 3 years to $6.00, and by 20 times within 5 years to $12.00 per share.
Because InferX is pioneering a next-generation technology and currently has modest revenues, we recommend that investors commit no more than 1 percent of their equity portfolio to NFRX common shares. Just last week InferX stock advanced sharply because of an announcement concerning a significant contract.
Summary Financial Table for InferX (NFRX.ob):
Current Price $0.60
Target Price May 10, 2011 $1.20
Target Price February 10, 2012 $1.80
Target Price February 10, 2014 $6.00
Target price February 10, 2016 $12.00
Shares Outstanding 17.3 million
Shares Fully Diluted 29.4 million
Market Capitalization $ 10.4 million
Est. Earnings per Share – 2011 $ -0.02
Est. Cash Flow per Share – 2011 $ 0.01
InferX (NFRX) is a market leader in next-generation distributed Predictive Analytics (PA) software solutions. InferX pioneered and commercialized a powerful, patented group of advanced analytical solutions which direct decision making and improve corporate performance. InferX targets its sophisticated solution toward select sub-sectors in the healthcare, public sector, industrial product, retail, and financial service industries in order to address significant Return on Investment opportunities.
PA enterprise software solutions directs decision making by applying advanced analytics and decision organization to a client organization’s enterprise data, with the objective of improving the client’s business processes to meet its specific organization goals. The PA solution accomplishes this through the application of advanced algorithms that process historical data, “learn” what has occurred in the past, and create “real time” business decisions within the client’s organization.
Traditional business intelligence (BI) tools extract relevant data in a structured way, aggregate and present it in formats such as dashboards and reports. BI tools are more exploratory than decision-oriented, helping businesses understand performance and trend, but generally not directing future actions or decisions based on what has been observed. Any attempts at using BI platforms to offer predictive insights are based on “deductive” technology (i.e., regression analysis) where “experts” create initial rules or hypotheses about the patterns and relationships that exist within the data based on their personal experience (i.e., who is a credit risk, what parameters create a potential risk, what medical indicators suggest a possible adverse drug reaction, etc.). Therefore, decisions based on a deductive approach are only as good as the initial rules, hypotheses, or data variables that directed the analysis.
By contrast, Predictive Analysis enterprise software solutions are based on “inductive” technology. PA does not presume initial rules or hypotheses about patterns and relationships that could exist within the data. Rather, PA lets data lead the way and employs statistics, machine learning, neural computing, robotics, computational mathematics, and artificial intelligence techniques to explore all the data, instead of utilizing a narrow subset of it, to ferret out meaningful relationships and patterns. This approach allows PA to identify insights and relationships among different variables, particularly ones that are outside conventional thinking.
InferX’s next-generation PA solution differentiates itself from traditional PA solutions in that it operates best in a distributed data environment. Instead of having to move data from different locations and servers into data warehouses to perform analysis, the next generation distributive PA solution brings the analysis directly to the data. InferX’s distributed solution is patented and enhances analytical speed, data privacy, and security while reducing cost.
In 2009, InferX merged with the Irus Group, a BI consulting and services firm specializing in the planning, implementation, and development of complex BI and corporate performance management solutions for government, financial services, retail, and healthcare clients. Since its founding, Irus Group has conducted engagements for over 200 clients, including Master Card, JPMorgan Chase, ConAgra, US Navy, US Army, US Air Force, and Peace Corps. The merger provides InferX additional financial support in advance of the full roll-out of InferX’s enterprise software solutions, and it serves as a valuable source of sales leads for the PA enterprise software product.
Disclosure:
The information contained in this Report contains forward-looking statements relating to the developments of the featured company’s products, services and future operating results or the future of the market. Statements contained in writing or in interviews are subject to certain risks and uncertainties that could cause actual results to differ materially from those projected.
The words “believe,”, “expect,” “intend,” “anticipate,” variations of such words, and similar expressions identify forward-looking statements, but their absence does not mean that the statement is not forward-looking. These statements are not guarantees of future performance and are subject to certain risks, uncertainties and assumptions that are difficult to predict. Factors that could affect performance include, but are not limited to, those factors that are discussed in each Company’s most recent reports and/or registration statements filed with the Securities and Exchange Commission. Visitors to this Internet Site are cautioned not to place undue reliance on these forward-looking statements. These statements have not been independently verified by the officers, directors or employees of Corporate Profile, LLC .com.
The information on this Internet Site has been submitted by journalists and analysts or provided by the companies contained herein or other sources believed to be reliable. Corporate Profile, LLC has not independently verified the information provided to it by third parties. Each individual should perform his or her own independent analysis before investing. The information contained herein is neither an offer nor a solicitation to buy any of the securities of the companies contained herein. Investing in securities is speculative and contains a high element of risk.
Here's a nice forecast .... Link http://www.cpreports.com/?p=861
You Are Here: Home » CP Reports Blog » RAY DIRKS Research: NFRX.pk Feb 8, 2011 by Ray Dirks
RAY DIRKS Research: NFRX.pk Feb 8, 2011 by Ray Dirks
Posted on admin on February 9, 2011 // Leave Your Comment InferX Corporation (NFRX.pk) – $0.60
February 7, 2011
RAY DIRKS Research recommends InferX Corporation (NFRX.pk) at its current price of 60 cents per share for substantial capital appreciation over the next 6 months, 1 year, 3 years, and 5 years. Headquartered in Northern Virginia near the Dulles International airport, InferX’s top management team and its 25 full-time employees plus 30 consultants are capable of leading the accelerating worldwide trend of Predictive Analysis (PA) by utilizing its 6 key patents (2 granted and 4 pending) in such significant areas as healthcare, insurance, government, finance, retail, and sales and marketing of industrial products.
Specifically, RAY DIRKS Research believes that the common stock of InferX will appreciate by 100% within 3 months to $1.20, triple within 1 year to $1.80, appreciate by 10 times within 3 years to $6.00, and by 20 times within 5 years to $12.00 per share.
Because InferX is pioneering a next-generation technology and currently has modest revenues, we recommend that investors commit no more than 1 percent of their equity portfolio to NFRX common shares. Just last week InferX stock advanced sharply because of an announcement concerning a significant contract.
Summary Financial Table for InferX (NFRX.ob):
Current Price $0.60
Target Price May 10, 2011 $1.20
Target Price February 10, 2012 $1.80
Target Price February 10, 2014 $6.00
Target price February 10, 2016 $12.00
Shares Outstanding 17.3 million
Shares Fully Diluted 29.4 million
Market Capitalization $ 10.4 million
Est. Earnings per Share – 2011 $ -0.02
Est. Cash Flow per Share – 2011 $ 0.01
InferX (NFRX) is a market leader in next-generation distributed Predictive Analytics (PA) software solutions. InferX pioneered and commercialized a powerful, patented group of advanced analytical solutions which direct decision making and improve corporate performance. InferX targets its sophisticated solution toward select sub-sectors in the healthcare, public sector, industrial product, retail, and financial service industries in order to address significant Return on Investment opportunities.
PA enterprise software solutions directs decision making by applying advanced analytics and decision organization to a client organization’s enterprise data, with the objective of improving the client’s business processes to meet its specific organization goals. The PA solution accomplishes this through the application of advanced algorithms that process historical data, “learn” what has occurred in the past, and create “real time” business decisions within the client’s organization.
Traditional business intelligence (BI) tools extract relevant data in a structured way, aggregate and present it in formats such as dashboards and reports. BI tools are more exploratory than decision-oriented, helping businesses understand performance and trend, but generally not directing future actions or decisions based on what has been observed. Any attempts at using BI platforms to offer predictive insights are based on “deductive” technology (i.e., regression analysis) where “experts” create initial rules or hypotheses about the patterns and relationships that exist within the data based on their personal experience (i.e., who is a credit risk, what parameters create a potential risk, what medical indicators suggest a possible adverse drug reaction, etc.). Therefore, decisions based on a deductive approach are only as good as the initial rules, hypotheses, or data variables that directed the analysis.
By contrast, Predictive Analysis enterprise software solutions are based on “inductive” technology. PA does not presume initial rules or hypotheses about patterns and relationships that could exist within the data. Rather, PA lets data lead the way and employs statistics, machine learning, neural computing, robotics, computational mathematics, and artificial intelligence techniques to explore all the data, instead of utilizing a narrow subset of it, to ferret out meaningful relationships and patterns. This approach allows PA to identify insights and relationships among different variables, particularly ones that are outside conventional thinking.
InferX’s next-generation PA solution differentiates itself from traditional PA solutions in that it operates best in a distributed data environment. Instead of having to move data from different locations and servers into data warehouses to perform analysis, the next generation distributive PA solution brings the analysis directly to the data. InferX’s distributed solution is patented and enhances analytical speed, data privacy, and security while reducing cost.
In 2009, InferX merged with the Irus Group, a BI consulting and services firm specializing in the planning, implementation, and development of complex BI and corporate performance management solutions for government, financial services, retail, and healthcare clients. Since its founding, Irus Group has conducted engagements for over 200 clients, including Master Card, JPMorgan Chase, ConAgra, US Navy, US Army, US Air Force, and Peace Corps. The merger provides InferX additional financial support in advance of the full roll-out of InferX’s enterprise software solutions, and it serves as a valuable source of sales leads for the PA enterprise software product.
Disclosure:
The information contained in this Report contains forward-looking statements relating to the developments of the featured company’s products, services and future operating results or the future of the market. Statements contained in writing or in interviews are subject to certain risks and uncertainties that could cause actual results to differ materially from those projected.
The words “believe,”, “expect,” “intend,” “anticipate,” variations of such words, and similar expressions identify forward-looking statements, but their absence does not mean that the statement is not forward-looking. These statements are not guarantees of future performance and are subject to certain risks, uncertainties and assumptions that are difficult to predict. Factors that could affect performance include, but are not limited to, those factors that are discussed in each Company’s most recent reports and/or registration statements filed with the Securities and Exchange Commission. Visitors to this Internet Site are cautioned not to place undue reliance on these forward-looking statements. These statements have not been independently verified by the officers, directors or employees of Corporate Profile, LLC .com.
The information on this Internet Site has been submitted by journalists and analysts or provided by the companies contained herein or other sources believed to be reliable. Corporate Profile, LLC has not independently verified the information provided to it by third parties. Each individual should perform his or her own independent analysis before investing. The information contained herein is neither an offer nor a solicitation to buy any of the securities of the companies contained herein. Investing in securities is speculative and contains a high element of risk.
Think we should have a (SaaS) model in the cloud if possible.Would bring in recurring revenue,just a thought.
10-20,000 per trade is what you're talking about and how many times along the way, i don't know off hand, twenty or more
amazing to me too, I would love to see some amazing validation soon
amazing runner we have here. the size of the individual buy orders amaze me, the average dollar amount per trade has been pretty high...
People chase so many awful plays, I'm surprised there are not more here on this one, just a handful, unbelievable
Well one thing that is actually mind boggling is that the price has went from .05 to .60 with basically no news....tells me that something really big is going on behind the scenes....I think a dollar is certainly in the cards before too much longer
Funny thing about the buyer, he always raises the ask when he buys so they cannot flip it seemingly.
How about something about their first Commercial Contract, that would be a great PR, here's to wishful thinking
No dought the PERFECT OPPORTUNITY if they ever wanted to get this above a dollar.
A buy of over 12K dollars just sent the MMs running for cover....ask now .99.....I think we are seeing a pretty good indication that the float is pretty close to dry....could get interesting with any buying, maybe the right time for the PR company to come out with something
Yea it won't take very much......once that happens I think we will see an entirely different group of investors getting involved
A Little volume and this thing busts over a dollar
Nite moved from .59 to 2.00
Just a matter of time. The company is taking all of the right steps to be very successful. As I said over a year ago, there is a plan in place to make the right people very aware of this stock and the potential that is there. There are very few shares available as we saw with the buying the last few weeks. Most of the shares are tied up in hands that have no intention of selling any time soon.
The PR firm will be getting the word out to the every day investor over the next few months and I think you will see many contracts announced. More and more every day investors will become aware of this company and the potential that is there but the real meat is when the stock price gets over a dollar and investors with a little more clout can become involved. This is all my opinion but I don't think that day is very far in the future.
I loved this stock over two years ago when I started buying it and I love it even more today. Anyone who watched the trading the last month should have a pretty good idea where this is heading. Those $15,000 buys were not by speculators.
Of course this is nothing more then my opinion which means absolutely nothing, just ask my wife.
Yeah, I would love to see a contract from the public sector, I really believe that would get the ball rolling.
The first of what will hopefully be many contract announcements by the company. I believe this is only the beginning but like I have said in the past, this company continue to be very under valued. After making a nice steady move up from the .05 range, the stock has been consolidating here around .50 I think it is only getting warmed up but that is nothing more then my opinion.
well you saw about a month ago there were (2) different 350,000 share trades a week apart
sure is. oddly big dollar volume for such a low number of trades
First buy of the day $23500 , 50,000 shares at the ask .47
amazing to me
i think dollarland. golden cross is a nice long term reversal signal, although we do have a low volume history. there has recently been steady volume at the ask. without any news and any precendent, someone has to know something the general public does not. that coupled with the announcement of the PR firm, makes me believe there will be an awareness campaign soon to get this pps higher.
So what are u saying Stoli? Are we going to Dollars soon or back to single pennies? What do ya think?
I would love to see the new PR firm jump into action soon.
If this ever breaks .60 it could be blue skys ahead big time
I think we need some catalyst news or something to go higher, looks like the buying stopped at .50
Do not let the maket makers have your shares,you"ll be sorry.Just my opinion.
there goes the buyer need some good news for support and volume
We get any sustained buying with positive news could easily breach the (DOLLAR) range .Think this become a real company ,not a pink sheets pump and dump.I have faith in this management team.
Do you think they're buying at .40 to sell at .25, not me I think this is going to dollars sooner than later, something's going on here, significant buying for over a month now, can't be alot left
GULP! 18000 at .40 like it was nothing, maybe institutional or fund buing?
Is this buyer amazing, one buyer buting up the float seemingly, no
Maybe we will seethe 52 week high soon (.49)
Followers
|
18
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
2266
|
Created
|
10/09/08
|
Type
|
Free
|
Moderators |
InferX 2.0 (Merger of InferX and The Irus Group)
We announced our intent to merge with The Irus Group to optimize the business and build shareholder value. Since August 2008 we have been working with The Irus Group under an MOU which laid the foundation of working with them as a partner and then specific teaming opportunities in Healthcare and Government sector. The significant synergies and close cooperation between InferX and The Irus Group led to the decision to merge. Irus Group is a top business intelligence and corporate performance management solution provider that works with several major financial services firms and government organizations to turn their data into information and their information into knowledge, which leads to better business decisions. This business objective is similar to the focus of InferX. The Irus Group also has a long history of providing planning and budgeting solutions to financial management at some of the world's largest commercial and government customers which will help InferX 2.0 capitalize on cross selling opportunities for our product suite. The Irus Group's 2008 revenues were approximately $6.0 million, and it is profitable. To comply with SEC rules, its financial statements are being audited by InferX's auditors.
We believe that the clients of the impacted businesses, as well as InferX shareholders, will be in a better position to optimize value as a result of this merger. We will continue to manage our businesses with this principle in mind, and we are focused on delivering results that support InferX 2.0. We made a series of structural changes as we entered in the New Year: integrating our organization structure, bringing new leaders, enhancing capital management, and better aligning our incentive structure to promote sales of products and solutions. We are at a crossroads and making important decisions in 2009 about the company we aspire to be. Altering the mix of businesses that compose InferX was among the most transformational actions taken until now.
As part of InferX 2.0, we adopted a principle that we would only participate in businesses where we either have - or could project - a clear path to a leadership. As a merged entity, we believe we possess those characteristics in our financial businesses; we determined that operating in the Government Sector, Healthcare Sector and Financial Services Sector would allow us to maximize shareholder value. Although our first priority is the integration of The Irus Group, we will continue to consider opportunities to expand our scale and differentiation through acquisition.
Innovation is also a driving force of InferX 2.0. We are grateful to our technical management team and believe that their creativity, innovation and tenacity will produce even greater results in the future. It is our people who continue to make the difference.
As management, we know that our ultimate responsibility is to provide value to clients and strong returns for shareholders. Regardless of near-term share price performance, we are confident that we have taken the actions that should provide attractive returns for our shareholders for many years.
The New InferX
Inside the company we refer to ourselves as "The New InferX" to reflect the many actions we are taking in 2009 and the vast opportunities we believe await us. We have lot of work ahead of us and once the complete integration has taken place and reporting is done for Q2 2009, we will be able to share forward looking pro-forma projections of The New InferX with our shareholders. We have a low capital business model which we believe will deliver attractive earnings, operating margins and cash flow.
We enter 2009 with what we believe will make us the leading provider of next generation business intelligence and predictive analytics solutions for the broad financial services industry. We offer a variety of leading solutions in healthcare fraud, financial services risk management and complex intelligence analysis in the government sector. Our goal is to not only deliver the products that we have today, but to increase integration and innovation so that we can provide even more client value in the future. That is the essence of The New InferX.
We envision The New InferX playing a larger role with increased focus on the end-users of our technology. We are increasing our thought leadership and product innovation to ensure that InferX clients are the beneficiaries of the best technology solutions available.
We believe that our shareholders will benefit from a strong focus on profitable growth during 2009. We are developing a new business model that focuses on recurring revenue and that is based on achieving profitability. We expect to extend our broad operating competencies across an enterprise to enhance the results from licensing our software suite and to generate cash flow that will be managed with the goal of optimizing shareholder value.
B.K.Gogia
Chairman of the Board
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |